An interventional study of sophrology sessions and Morphee Device in Breast Cancer Female, sponsored by Institut Cancerologie de l'Ouest. Recruiting at 3 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Institut Cancerologie de l'Ouest · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest — 7 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Institut Cancerologie de l'Ouest.
Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 31st registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+
Institut Cancerologie de l'Ouest · Sites in France
Ages 40+ · Women only
Institut Cancerologie de l'Ouest
Ages 18+ · Women only
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 63 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 140 across the 23 interventional studies, 195 across the 12 observational. Of the 20 that completed or were terminated, 4 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
2 of the studies in Breast Neoplasms by Institut Cancerologie de l'Ouest that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962163Institut Cancerologie de l'OuestAssessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients | 2027-06 |
| NCT06800989Institut Cancerologie de l'OuestTo Assess the Contribution of Sophrology Assisted by an Ambulatory Device on the Anxiety of Patients Undergoing Chemotherapy for the Treatment of Localized Breast Cancer | 2027-08-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with localized breast cancer undergo treatment that includes breast surgery, which always alters their body image, complemented by optional additional treatments depending on the specifics and severity of their disease. These treatments are multimodal and may include chemotherapy, radiotherapy, targeted anticancer treatments, and hormone therapy, followed by prolonged monitoring for at least 5 years.
A recent study showed that the announcement of cancer and its treatments is a source of reactive anxiety for 47% of patients at the time of diagnosis, which can be associated with depression in 59% of cases before chemotherapy. Anxiety increases with the intensity of treatments and is higher when chemotherapy is administered, especially in younger patients (under 50 years old).
The integrative multidisciplinary care available in treatment centers (psychologist, adapted physical activity, socio-aesthetician), combined with external support through associative networks (art therapy, music therapy, etc.), is crucial for improving quality of life and treatment side effects. Sophrology is one of these complementary therapies recommended by Association Francophone Des Soins Oncologiques De Support (French Association for Supportive Care in Oncology) within or outside the healthcare structure and is validated as supportive care. Its principle is to positively enhance patients' qualities and resources by altering states of consciousness, allowing individuals to find a balance between their thoughts, emotions, and behaviors. The three fundamental principles are to bring the body schema to a more lived reality, reinforce positive action, and develop objective reality. The "mindfulness" techniques used in sophrology include dynamic relaxation and sophronizations. Sophrology is based on the scientific principles of mindfulness meditation (developing attentional resources and body awareness by modulating brain waves).
Studies have shown the benefits of mindfulness in managing stress, certain psychosomatic conditions, and chronic pain. Improvements in overall quality of life, stress symptoms, and sleep quality have been reported in the evaluation of a mindfulness meditation program for cancer patients. A trial demonstrated the beneficial effect of group mindfulness meditation on the anxiety of women who had undergone chemotherapy for breast cancer.
Today, although sophrology is regularly used in medical care, no robust scientific study has evaluated its benefit in oncology. Institut National de la Santé et de la Recherche Médicale, together with Haute Autorité de la Santé, highlighted in its 2020 report on sophrology the significant need to scientifically assess the interest of sophrology in medical care.
However, the use and accessibility of complementary therapies, including sophrology, are very unequal across France and depend on hospitals, geography, patient mobility, and sometimes the financial ability of patients to access paid complementary therapies. As a result, many anxious patients cannot access sophrology sessions at the desired time due to geographical, accessibility, human resource, and sometimes financial reasons (outside the hospital).
The Morphée® device could help reduce these disparities and accessibility issues by allowing patients to perform a sophrology session at any time and place after receiving explanations from a healthcare professional.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's planned enrollment of 63 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Morphée® device is an easy-to-use ambulatory sophrology tool in French. Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist. Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on Cycle 1 Day 1 or within a maximum of 3 weeks following Cycle 1 Day 1. The second session (S2) should be conducted within 3 to 4 weeks after the first session
In the control arm, patients will be managed according to current recommendations, including information and access to support care available in the investigator centers. After participation in the study, patients may be offered a session of sophrology at the investigator's discretion.
Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on Cycle 1 Day 1 or within a maximum of 3 weeks following Cycle 1 Day 1. The second session (S2) should be conducted within 3 to 4 weeks after the first session.
Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist.
To measure the evolution of anxiety in patients undergoing adjuvant or neoadjuvant chemotherapy treatment, depending on whether they benefit from a sophrology program through an ambulatory sophrology device (Morphée®)
Anxiety evaluated with Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains
Time frame: Inclusion and 3 months after start of treatment
Not enrolling at this site.
Not enrolling at this site.
Started May 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 27 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Cancerologie de l'Ouest →